Ascletis Pharma Inc. (ASCLF.PK) Wednesday reported positive interim results from the Phase 1b study of ASC30 for the treatment of obesity.
The Phase Ib multiple ascending dose (MAD) study consists of 3 cohorts. In each cohort, eight patients were treated with ASC30 and 2 were on placebo. The average daily dose over the 28-day treatment period was 9.25 mg ASC30 for cohort 1, and 18 mg for cohort 2.
Interim results from the study showed mean body weight reductions from baselines of 4.3% and 6.3% for cohorts 1 and 2, respectively, after the 28-day treatment period. Further, the drug candidate was well tolerated with no reports of serious adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.